Internet-Based, Parent-Led Cognitive-Behavioral Therapy for Anxiety in Youth With ASD

Sponsor
Baylor College of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT05284435
Collaborator
(none)
256
1
2
17.1
14.9

Study Details

Study Description

Brief Summary

This study compares the effectiveness of two levels of therapist support for an internet-based, parent-led cognitive behavioral therapy for youth with anxiety and ASD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy-Email (iCBT-E)
  • Behavioral: Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)
N/A

Detailed Description

Autism spectrum disorder, or ASD, is one of the most common neurodevelopmental disorders, affecting up to 1 out of 59 youth in the United States. Anxiety disorders affect 50-80% of children with ASD and are associated with significant life impairment and worsening trajectory without treatment. Cognitive-behavioral therapy (CBT) is an effective treatment for anxiety, yet access to CBT is very limited for most families due to the cost, practicalities of attending in-person treatment sessions and limited availability of trained therapists. Access to CBT is particularly limited for Hispanic or Spanish-speaking families due to lack of services provided in Spanish. Web-based or internet-based delivery of services is a promising method to improve access to care for youth with ASD and their families, given its reachability to a wider range of areas (e.g., rural/underserved) and its ability to minimize practical barriers (e.g., treatment could be delivered to home without need for travel), and reduce stigma (e.g., parents do not need to visit mental health clinics). Thus, the goal of this project is to increase access to care for families of children with ASD and anxiety through an internet-based treatment intervention model. This intervention, developed by the study team, consists of an interactive website with treatment materials that parents can work through with their child, both in English and Spanish.

Specifically, this project will examine the effectiveness of an internet-based, parent-led cognitive-behavioral therapy (iCBT) for anxiety in children with two levels of therapist support: 1) iCBT-E (therapist support is delivered via email) and 2) iCBT-EV (therapist support is delivered via email and videoconferencing sessions).

This study will also involve two phases: 1) pilot intervention phase and 2) randomized controlled phase.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
256 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Internet-Based, Parent-Led Cognitive-Behavioral Therapy for Anxiety in Youth With ASD
Actual Study Start Date :
Mar 28, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: iCBT-Email (iCBT-E)

Parents will receive a weekly email from a therapist over the 12 weeks of treatment.

Behavioral: Cognitive Behavioral Therapy-Email (iCBT-E)
Participating families will receive an access to the website that contains treatment materials for both parent and child. During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently.

Active Comparator: iCBT-Email and Videoconferencing (iCBT-EV)

Parents will receive a weekly email and six 30-minute supportive video calls with a therapist over the 12 weeks of treatment.

Behavioral: Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)
Participating families will receive an access to the website that contains treatment materials for both parent and child. During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed.

Outcome Measures

Primary Outcome Measures

  1. 5-item Pediatric Anxiety Rating Scale - Autism Spectrum Disorder [7 days]

    Clinician rated child anxiety severity throughout the past week. Each item is scored on a 0 to 5 scale (higher scores correspond to greater severity), yielding a total between 0 and 30.

  2. Clinical Global Impression-Improvement [7 days]

    Clinician rated child psychopathology improvement since initial rating. A single item is scored 0-6 (0 = very much worse; 6= very much improved).

Secondary Outcome Measures

  1. Revised Child Anxiety and Depression Scale- Parent-Report- Anxiety Subscale [7 days]

    Parent rated child anxiety severity. It is a 37-item scale and each item is scored on a 0 ("never") to 3 ("always") scale (higher scores correspond to greater severity), yielding a total between 0 to 111.

  2. Revised Child Anxiety and Depression Scale- Self-Report- Anxiety Subscale [7 days]

    Child rated anxiety severity. It is a 37-item scale and each item is scored on a 0 ("never") to 3 ("always") scale (higher scores correspond to greater severity), yielding a total between 0 to 111.

  3. Social Responsiveness Scale, Second Edition [7 days]

    Parent rated child impairment in social behaviors. It is a 65-item scale and each item is scored on a 1 ("not true") to 4 ("almost always true") scale (higher scores correspond to greater impairment), yielding a total raw score between 65 and 260.

  4. Sheehan Disability Scale [7 days]

    Parent rated child functional impairment. It is a 5-item scale and each item is scored on a 0 ("not at all") to 10 ("extremely") scale (higher scores correspond to greater impairment), yielding a total between 0 and 50.

Eligibility Criteria

Criteria

Ages Eligible for Study:
7 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Child is between the ages 7-15 years at consent/assent.

  • The child meets criteria for ASD.

  • The child meets criteria for clinically significant anxiety and/or OCD symptoms.

  • Anxiety and/or OCD is the primary presenting problem.

  • One parent/guardian is able and willing to participate.

  • The child has a Full Scale and Verbal Comprehension Intelligence Quotient >70.

  • The child is able to communicate verbally.

  • Participants must reside in Texas and must be in the state of Texas when taking calls.

Exclusion Criteria:
  • The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and/or intellectual disability.

  • The child has severe current suicidal/homicidal ideation and/or self-injury requiring medical intervention.

  • The child is receiving concurrent psychotherapy for anxiety.

  • Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant/psychoactive medication less than 2 weeks prior to study enrollment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Baylor College of Medicine Houston Texas United States 77030

Sponsors and Collaborators

  • Baylor College of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrew Guzick, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT05284435
Other Study ID Numbers:
  • H-51359
First Posted:
Mar 17, 2022
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022